Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 265 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5% albumin Clear all
Completed Phase 2 Interventional Results available

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT01818063
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Veliparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 13, 2026, 4:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

NCT03174275
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
Interventions
Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 13, 2026, 4:48 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

NCT00662129
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
92
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

NCT00287235
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions
MARS, Standard Medical Therapy
Device · Drug
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients

NCT02654782
View directory record Official record
Conditions
Hemodynamic Stability
Interventions
Lactated Ringer's, 5% Human Albumin
Drug
Lead sponsor
William C. Oliver
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Early Phase 1 Interventional

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

NCT03600623
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
Interventions
Folfirinox, Gemcitabine nab-Paclitaxel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional Results available

Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

NCT00006099
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Monoclonal antibody hu3S193
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional Results available

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

NCT00006046
View directory record Official record
Conditions
Colorectal Cancer
Interventions
monoclonal antibody hu3S193
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

NCT00249002
View directory record Official record
Conditions
Hemodialysis Graft Dysfunction
Interventions
ABI-007
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Peoria, Illinois • Shreveport, Louisiana • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

NCT01220154
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
Interventions
Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
David O'Malley
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2023
U.S. locations
1
States / cities
Hilliard, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

NCT02715531
View directory record Official record
Conditions
Solid Tumor
Interventions
5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

NCT00585689
View directory record Official record
Conditions
Bladder Cancer
Interventions
ABI-007, Carboplatin, Gemcitabine, Radical Cystectomy
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT03840915
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

NCT01632306
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 13, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

NCT07024615
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

NCT03918278
View directory record Official record
Conditions
Neoplasms
Interventions
MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

NCT00544648
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, nab-paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Paducah, Kentucky • Portland, Oregon • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer

NCT02172846
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Proton beam radiation therapy (PBT), Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 13, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

NCT03631199
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

NCT02620800
View directory record Official record
Conditions
Metastatic Pancreas Adenocarcinoma
Interventions
5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 13, 2026, 4:48 PM EDT
Completed Phase 3 Interventional

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

NCT04229004
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 13, 2026, 4:48 PM EDT